Announcement • Aug 14
Arecor Therapeutics plc Publishes Clinical Data for AT278 in Peer-Reviewed Journal Arecor Therapeutics plc announced the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity & Metabolism. The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic (PK) and pharmacodynamic (PD) profile regardless of body mass index (BMI) levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy. This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association's (ADA) Scientific Sessions. The published study, A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI, evaluated the PK, PD and safety of AT278 (500U/mL) compared with standard concentration (U100; 100U/mL) insulin aspart and U500 human regular insulin (500U/mL). Key study findings include: AT278 exhibited a significantly faster insulin absorption than both standard U100 concentration insulin aspart and U500 human regular insulin. Faster absorption led to a significantly greater glucose-lowering effect within the first hour following administration. AT278 maintained its ultra-rapid onset characteristics independent of BMI, distinguishing it from standard insulin apart. Overall, insulin exposure and glucose-lowering activity remained comparable while maintaining a favourable safety profile. AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems. Announcement • Apr 29
Arecor Therapeutics plc, Annual General Meeting, May 28, 2026 Arecor Therapeutics plc, Annual General Meeting, May 28, 2026. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom 
